Tissue Engineering Part B-Reviews is a premier academic journal published by MARY ANN LIEBERT, INC, focusing on the interdisciplinary field of tissue engineering and regenerative medicine. With an impressive impact factor that places it in the Q1 category across multiple relevant fields—including Biochemistry, Bioengineering, Biomaterials, and Biomedical Engineering—this journal provides a vital platform for researchers and professionals to disseminate cutting-edge findings and comprehensive reviews. Covering a vast scope from 2008 to 2024, the journal is committed to advancing knowledge in the application of engineering principles to biological tissues, making it an indispensable resource for those at the forefront of biomedical innovation. While the journal does not currently offer open access options, its rigorous peer review process ensures high-quality contributions that are essential for academic and practical advancements. The journal's rankings in Scopus reflect its significance, catering to a diverse audience of students, researchers, and practitioners seeking the latest insights in this dynamic field.

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

Materials Science & Engineering C-Materials for Biological Applications is a premier journal published by ELSEVIER, dedicated to advancing the field of biomaterials through interdisciplinary research. With a robust ISSN of 0928-4931, this journal has made its mark in the realms of Chemical Engineering and Materials Science, achieving impressive Scopus rankings within its categories, namely Rank #16/151 in Bioengineering (89th percentile) and Rank #13/112 in Biomaterials (88th percentile). Although the journal's coverage in Scopus has been discontinued since 2021, it remains a critical resource for researchers, professionals, and students eager to explore innovative materials and their applications in biological contexts. The journal’s open access policy enhances its accessibility, fostering a global exchange of knowledge and inspiring future advancements in the field of materials science.

Materials Today Bio, published by Elsevier, is an esteemed open-access journal dedicated to advancing the fields of bioengineering, biomaterials, and biomedical engineering. Since its inception in 2019, this journal has quickly made a name for itself, currently ranked Q1 in multiple categories including Bioengineering, Biomaterials, and Biotechnology, reflecting its exceptional quality and relevance in the rapidly evolving landscape of bio-related sciences. With an impressive Scopus ranking positioning it in the top 25% of its categories, Materials Today Bio provides a vital platform for researchers and professionals to share cutting-edge discoveries and innovative applications that bridge the gap between materials science and biological studies. Accessible to a global audience, this journal not only fosters collaboration among the scientific community but also aims to highlight significant advancements in cell and molecular biology, making it an indispensable resource for students and seasoned experts alike. The journal's commitment to open access since 2019 underscores its dedication to disseminating knowledge widely, ensuring that crucial findings reach those who can benefit from them the most.

International Journal of Nanomedicine, published by DOVE MEDICAL PRESS LTD, is a leading open access journal dedicated to advancing the field of nanomedicine and its applications in healthcare. Since its establishment in 2006, the journal has grown significantly, now encompassing a wide array of topics including bioengineering, biomaterials, biophysics, drug discovery, and pharmaceutical sciences, and is recognized in Q1 quartiles across major categories like *Nanoscience and Nanotechnology* and *Organic Chemistry*. The journal boasts an impressive standing within the Scopus rankings, with high percentiles across various related fields, making it an invaluable resource for researchers, professionals, and students seeking to stay informed on the latest innovations and developments in nanomedicine. With its commitment to fostering an accessible and collaborative academic environment, the International Journal of Nanomedicine serves as a vital platform for disseminating transformative research that impacts scientific practice and healthcare outcomes globally.

Advanced Therapeutics, published by WILEY in the United Kingdom, stands at the forefront of medical and pharmaceutical research, offering invaluable insights from 2018 to 2024. This distinguished journal, with an E-ISSN of 2366-3987, is recognized for its exceptional academic rigor, boasting an impressive array of Q1 categorizations in essential fields such as Biochemistry (medical), Pharmaceutical Science, and Pharmacology. With its strategic focus on interdisciplinary studies and cutting-edge therapeutic developments, Advanced Therapeutics serves as a vital resource for researchers, professionals, and students keen on advancing their knowledge and contributing to the evolving landscape of medicine and genetics. The journal's high Scopus rankings further affirm its impact, with significant placements in multiple categories underscoring the quality of published research. Although the journal operates under a subscription model, its accessibility to high-impact findings ensures that it remains a pivotal platform for innovative discourse in therapeutics.

Materials is an esteemed journal published by MDPI, dedicated to advancing the fields of Condensed Matter Physics and Materials Science. With its commitment to Open Access since its inception in 2008, the journal has made significant strides in disseminating high-quality research globally, allowing researchers, professionals, and students easy access to cutting-edge studies without financial barriers. Hailing from Switzerland, the journal has shown remarkable growth and prominence, currently ranked in the Q2 quartile in its categories according to the latest assessments, which highlights its impact within the community. As the journal converges its focus from 2008 to 2024, it aims to continually foster a robust exchange of knowledge on innovative materials and their applications, thereby supporting the evolving landscape of science and technology. With an E-ISSN of 1996-1944 and a user-friendly platform, Materials is poised to be a leading choice for scholars eager to contribute to and engage with pioneering research.

Acta Biomaterialia, published by Elsevier Science Ltd, is a leading journal in the fields of biochemistry, biomaterials, biomedical engineering, biotechnology, and molecular biology. With an ISSN of 1742-7061 and an E-ISSN of 1878-7568, this prestigious journal has secured a remarkable position in the academic community, evidenced by its inclusion in the Q1 category across multiple disciplines for 2023. It ranks impressively at #21 in biochemistry, #16 in biomedical engineering, #18 in biotechnology, and #11 in biomaterials, reflecting its high impact and relevance to ongoing research and development. The journal provides a platform for disseminating innovative research and advancements in the design and application of biomaterials, contributing to scientific discussions that propel the field forward. Although it does not currently offer open access options, Acta Biomaterialia continues to attract contributions that advance our understanding of biomaterials and their interactions with biological systems, ensuring that researchers, professionals, and students remain informed about the latest trends and breakthroughs in this rapidly evolving area of study.

JOURNAL OF CONTROLLED RELEASE is a premier academic journal published by Elsevier that is dedicated to advancing the field of pharmaceutical science with a focus on drug delivery systems. Established in 1984, the journal has consistently served as a vital platform for disseminating high-quality research and innovative ideas in the area of controlled release technologies. With an impressive impact factor and ranking in the Q1 category of Pharmaceutical Science, it ranks #3 out of 183 in Scopus for its field, reflecting its influence and significance within the academic community, as noted by its percentile of 98th. The journal encompasses a wide range of topics, including polymer science, pharmacokinetics, and bioengineering, ensuring it remains at the forefront of pharmaceutical advancements. While currently not offering open access options, the journal serves a diverse audience of researchers, professionals, and students who are eager to push the boundaries of knowledge in drug delivery and therapeutics. For those looking to make impactful contributions in this dynamic field, JOURNAL OF CONTROLLED RELEASE is an essential resource for both foundational studies and cutting-edge research findings.

Biomedical Materials, published by IOP Publishing Ltd, is a premier journal dedicated to the rapidly evolving field of biomedical engineering and materials science. With a robust impact factor showcasing its influence, this journal serves as a vital platform for disseminating pioneering research from 2006 to 2024. Covering an array of interdisciplinary topics—ranging from biomaterials to bioengineering and applied chemistry—the journal consistently ranks in the second quartile across multiple categories including Bioengineering (Q2), Biomaterials (Q2), and Biomedical Engineering (Q2) as of 2023. Researchers, professionals, and students alike benefit from its contributions, exploring innovative solutions at the intersection of biology and material science. Although not an Open Access journal, Biomedical Materials remains essential in advancing our understanding and facilitating discussions surrounding state-of-the-art materials that revolutionize medical applications and enhance patient care.